ClinicalTrials.gg
CompletedNCT02760264Updated Jan 2, 2019Results posted

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase 2 interventional study of Vamorolone 0.25 mg/kg/day and Vamorolone 0.75 mg/kg/day in Duchenne Muscular Dystrophy, sponsored by ReveraGen BioPharma, Inc.. Completed at 12 sites in 6 countries. Open to male participants aged 4 Years to 6 Years. Per ClinicalTrials.gov, last updated 2019-01-02.

Sponsored by ReveraGen BioPharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
4 Years to 6 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
58th of 171
48 · median 25
Started
2016
with 14 others
Phase 2
57 of 232
4 open now
Registered
100th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 58th largest by enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2016, is one of 57 in phase 2, and was the 100th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 6 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and \< 7 years old.

Read the detailed description

This study will evaluate the safety and tolerability of a new steroid-like medication called vamorolone in boys with DMD ages ≥ 4 years and \< 7 years. Enrolled participants will take the study medication for 14 days followed by a 14 day follow-up period. The potential effectiveness of vamorolone in treating DMD will also be explored.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
  • vamorolone
04

Who can participate

Ages eligible
4 Years to 6 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's parent or legal guardian has provided written /Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;
  2. Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:

    1. Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR
    2. Identifiable mutation within the DMD gene (deletion/duplication of one or more exons) where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, OR
    3. Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon), with a typical clinical picture of DMD;
  3. Subject is ≥ 4 years and \< 7 years of age at time of enrollment in the study;
  4. Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as assessed at the Screening and Baseline Visits;
  5. Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not , in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total all must be ≤ at the Screening Visit);
  6. Subject has evidence of chicken pox immunity as determined by presence of IgG antibodies to varicella, as documented by a positive test result from the testing laboratory at the Screening Visit; and
  7. Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject has current or history of major renal or hepatic impairment, diabetes mellitus or ;
  2. Subject has current or history of chronic systemic fungal or viral infections;
  3. Subject has had an acute illness within 4 weeks prior to the first dose of study medication;
  4. Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
  5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
  6. Subject is currently being treated or has received previous treatment with oral or other immunosuppressive agents. [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
  7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;
  8. Subject has an allergy or to the study medication or to any of its constituents;
  9. Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
  10. Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;
  11. Subject is taking any other drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment; or
  12. Subject has previously been enrolled in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Dose Level Group 1

    Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.

    Drug: Vamorolone 0.25 mg/kg/day

  • Experimental
    Dose Level Group 2

    Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.

    Drug: Vamorolone 0.75 mg/kg/day

  • Experimental
    Dose Level Group 3

    Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.

    Drug: Vamorolone 2.0 mg/kg/day

  • Experimental
    Dose Level Group 4

    Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.

    Drug: Vamorolone 6.0 mg/kg/day

Interventions

  • DrugVamorolone 0.25 mg/kg/day

    Drug page: Vamorolone

    Oral administration of 0.25 mg/kg/day daily for 14 days.

    Also known as: VBP15

  • DrugVamorolone 0.75 mg/kg/day

    Drug page: Vamorolone

    Oral administration of 0.75 mg/kg/day daily for 14 days.

    Also known as: VBP15

  • DrugVamorolone 2.0 mg/kg/day

    Drug page: Vamorolone

    Oral administration of 2.0 mg/kg/day daily for 14 days.

    Also known as: VBP15

  • DrugVamorolone 6.0 mg/kg/day

    Drug page: Vamorolone

    Oral administration of 6 mg/kg/day daily for 14 days.

    Also known as: VBP15

06

What researchers measure

Primary outcomes

  1. Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03

    Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group

    Time frame: Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.

Secondary outcomes

  1. Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Week 2

  2. Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Week 2

  3. Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline , Week 2

  4. Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Week 2

  5. Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Week 2 (pre-dose)

  6. Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Day 1, Week 2, Week 4

  7. Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline Day 1 Week 2 Week 4

  8. Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Day 1, Week 2, Week 4

  9. Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides

    Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

    Time frame: Baseline, Day 1, Week 4

  10. Pharmacokinetic (PK) Assessments (Tmax)

    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.

    Time frame: Day 1, Week 2

  11. Pharmacokinetic (PK) Assessments (AUC Inf)

    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.

    Time frame: Day 1, Week 2

  12. Pharmacokinetic (PK) Assessments CL (ml/hr/kg)

    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay

    Time frame: Day 1, Week 2

  13. Pharmacokinetic (PK) Assessments t(1/2)

    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.

    Time frame: Day 1, Week 2

  14. Pharmacokinetic (PK) Assessments (Cmax)

    Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay

    Time frame: Day 1, Week 2

  15. Metabolites in Safety Testing (MIST) Assessment

    A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.

    Time frame: Week 2 (Day 14)

07

Results

Posted Jan 2, 2019

Participant flow

0.25 mg/kg/Day
Participant flow — 0.25 mg/kg/Day
MilestoneVamorolone 0.25 mg/kg/DayVamorolone 0.75 mg/kg/DayVamorolone 2.0 mg/kg/DayVamorolone 6.0 mg/kg/Day
Started12000
Completed12000
Not completed0000
0.75 mg/kg/Day
Participant flow — 0.75 mg/kg/Day
MilestoneVamorolone 0.25 mg/kg/DayVamorolone 0.75 mg/kg/DayVamorolone 2.0 mg/kg/DayVamorolone 6.0 mg/kg/Day
Started01200
Completed01200
Not completed0000
2.0 mg/kg/Day
Participant flow — 2.0 mg/kg/Day
MilestoneVamorolone 0.25 mg/kg/DayVamorolone 0.75 mg/kg/DayVamorolone 2.0 mg/kg/DayVamorolone 6.0 mg/kg/Day
Started00120
Completed00120
Not completed0000
6.0 mg/kg/Day
Participant flow — 6.0 mg/kg/Day
MilestoneVamorolone 0.25 mg/kg/DayVamorolone 0.75 mg/kg/DayVamorolone 2.0 mg/kg/DayVamorolone 6.0 mg/kg/Day
Started00012
Completed00012
Not completed0000

Outcome measures

PrimaryOverall Summary of Adverse Events as Assessed by CTCAE Version 4.03

Treatment-emergent adverse events (TEAEs) are defined as any adverse event or worsening of an existing conditions after initiation of the investigational product and through the subject's last study visit (study completion or early termination). Serious adverse events were recorded for up to 30 days after the final administration of study drug. Note: Total Number of Treatment Emergent Adverse Events: The total incidences of TEAEs experienced in study; Any Treatment Emergent Adverse Event: TEAEs reported at least once per dose group

Time frame:
Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.
Reported as:
Number · Number of Events
Overall Summary of Adverse Events as Assessed by CTCAE Version 4.03
Number of EventsDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Total Number of Adverse Events16181311
Total Number of Treatment Emergent Adverse Events1313119
Any Treatment Emergent Adverse Events7687
Any Drug Related Treatment Emergent Adverse Events1223
Any CTCAE Grade 3 or Higher TEAE0000
Discontinuation of Study Drug due to TEAE0000
Any Serious Treatment Emergent Adverse Events0000
Death0000
SecondarySerum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Week 2
Reported as:
Mean · mg/ dL
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Fasting Glucose
mg/ dLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Baseline87.5 ± 9.4488.9 ± 18.7189.3 ± 7.9192.3 ± 8.19
Week 285.3 ± 9.2983.1 ± 6.6989.5 ± 5.2089.2 ± 11.12
Week 2 Change from Baseline-2.2 ± 10.46-5.8 ± 18.920.2 ± 8.79-1.3 ± 9.41
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Week 2
Reported as:
Mean · Week 2 % change from Baseline
Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose
Week 2 % change from BaselineDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Serum Pharmacodynamic Biomarkers (Insulin Resistance) -Fasting Glucose-1.8 ± 13.07-4.2 ± 13.980.8 ± 9.76-1.2 ± 9.80
SecondarySerum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline , Week 2
Reported as:
Mean · µIU/mL
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
µIU/mLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Baseline5.54 ± 3.6513.09 ± 2.0333.40 ± 1.5483.96 ± 2.027
Week 25.29 ± 2.6713.22 ± 1.9243.87 ± 2.1186.73 ± 4.599
Week 2 Change from Baseline-0.65 ± 2.9130.34 ± 1.2890.47 ± 2.7772.78 ± 4.651
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Week 2
Reported as:
Mean · Week 2 % change from Baseline
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin
Week 2 % change from BaselineDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Serum Pharmacodynamic Biomarkers (Insulin Resistance)- Insulin-5.54 ± 32.62226.07 ± 76.48342.85 ± 107.33783.55 ± 117.064
SecondarySerum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Week 2 (pre-dose)
Reported as:
Mean · mcg/dL
Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol
mcg/dLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Serum Pharmacodynamic Biomarkers (Adrenal Axis Suppression)- First in Morning Cortisol10.425 ± 1.73589.755 ± 2.76147.321 ± 3.03223.010 ± 1.0141
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Day 1, Week 2, Week 4
Reported as:
Mean · ng/mL
Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin
ng/mLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Baseline37.94 ± 11.62235.66 ± 6.80041.17 ± 5.61744.36 ± 5.979
Day 139.37 ± 14.18935.89 ± 7.52634.93 ± 6.88133.52 ± 9.135
Day 1 Change from Baseline1.43 ± 8.1970.23 ± 5.304-6.23 ± 10.930-11.37 ± 9.137
Week 238.53 ± 12.02535.10 ± 8.23837.51 ± 8.62429.04 ± 4.853
Week 2 Change from Baseline0.58 ± 5.986-0.56 ± 7.934-3.66 ± 9.818-15.32 ± 6.450
Week 439.20 ± 14.13642.24 ± 8.42647.91 ± 6.64842.81 ± 10.851
Week 4 Change from Baseline1.26 ± 5.6506.58 ± 9.3416.74 ± 9.747-1.55 ± 11.176
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Day 1, Week 2, Week 4
Reported as:
Mean · % change from Baseline
Serum Pharmacodynamics Biomarkers (Bone Turnover) -Osteocalcin
% change from BaselineDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 1 Percent Change from Baseline3.95 ± 22.0151.41 ± 15.449-12.63 ± 25.020-25.05 ± 20.228
Week 2 Percent Change from Baseline2.48 ± 16.756-0.07 ± 22.408-7.81 ± 23.664-33.87 ± 12.548
Week 4 Percent Change from Baseline2.72 ± 14.06320.91 ± 28.64418.74 ± 25.095-2.43 ± 25.932
SecondarySerum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline Day 1 Week 2 Week 4
Reported as:
Mean · ng/mL
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
ng/mLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Baseline555.8 ± 184.72480.7 ± 118.20508.2 ± 94.36511.5 ± 106.50
Day 1474.0 ± 116.45443.7 ± 112.38417.1 ± 87.35475.2 ± 147.10
Day 1 Change from Baseline-81.8 ± 124.24-34.5 ± 101.97-91.1 ± 64.64-36.5 ± 144.04
Week 2443.8 ± 93.86407.8 ± 96.54346.6 ± 68.59303.7 ± 56.38
Week 2 Change from Baseline-112.0 ± 125.08-70.6 ± 123.69-161.6 ± 73.52-207.8 ± 78.16
Week 4573.8 ± 251.02496.7 ± 117.57492.0 ± 81.92566.3 ± 149.32
Week 4 Change from Baseline18.1 ± 153.1021.3 ± 122.87-16.2 ± 79.6454.8 ± 118.09
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Day 1, Week 2, Week 4
Reported as:
Mean · % change from Baseline
Serum Pharmacodynamic Biomarkers (Bone Turnover)- Procollagen 1 N-Terminal Propeptide
% change from BaselineDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 1 Percent Change from Baseline-12.2 ± 17.07-5.4 ± 24.58-17.4 ± 12.59-5.7 ± 30.76
Week 2 Percent Change from Baseline-17.5 ± 14.65-11.2 ± 29.19-30.9 ± 11.80-39.9 ± 9.22
Week 4 Percent Change from Baseline2.8 ± 25.577.8 ± 30.86-1.4 ± 17.4711.8 ± 28.24
SecondarySerum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Day 1, Week 4
Reported as:
Mean · pg/mL
Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides
pg/mLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Baseline871.0 ± 160.85935.8 ± 286.50936.8 ± 256.25889.3 ± 186.68
Day 1974.8 ± 252.77940.8 ± 227.60838.3 ± 233.30786.8 ± 331.68
Day 1 Change from Baseline72.4 ± 241.87-12.9 ± 233.44-98.5 ± 237.69-115.7 ± 421.04
Week 2963.7 ± 157.68903.3 ± 251.01710.4 ± 180.03625.7 ± 203.19
Week 2 Change from Baseline85.0 ± 185.90-19.9 ± 266.99-226.4 ± 185.99-263.7 ± 229.69
Week 4915.9 ± 263.13983.5 ± 298.47949.8 ± 303.76989.2 ± 216.29
Week 4 Change from Baseline17.4 ± 267.4534.8 ± 271.5012.9 ± 181.4599.8 ± 211.90
Statistical analysis
  • Dose Level Group 1 vs Dose Level Group 2 vs Dose Level Group 3 vs Dose Level Group 4 ·
SecondarySerum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides

Pharmacodynamic biomarkers were measured to investigate the effects of single and multiple oral doses of vamorolone on serum PD biomarkers in ambulant boys ages 4-\< 7 years with DMD.

Time frame:
Baseline, Day 1, Week 4
Reported as:
Mean · % change from Baseline
Serum Pharmacodynamic Biomarkers (Bone Turnover)-Type I Collagen C-Telopeptides
% change from BaselineDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 1 Percent Change from Baseline9.9 ± 25.382.7 ± 23.76-8.0 ± 23.93-6.7 ± 53.72
Week 2 Percent Change from Baseline11.9 ± 20.522.2 ± 26.44-22.5 ± 15.27-27.7 ± 26.50
Week 4 Percent Change from Baseline3.6 ± 28.966.8 ± 24.062.7 ± 19.0314.5 ± 32.98
SecondaryPharmacokinetic (PK) Assessments (Tmax)

Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. tmax= time when plasma concentration is at maximum.

Time frame:
Day 1, Week 2
Reported as:
Mean · hour
Pharmacokinetic (PK) Assessments (Tmax)
hourDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 13.6 ± 1.24.6 ± 2.12.5 ± 1.32.7 ± 1.3
Week 23.8 ± 1.803.8 ± 2.22.8 ± 12.3 ± 0.86
SecondaryPharmacokinetic (PK) Assessments (AUC Inf)

Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. AUC inf= Area under the concentration vs. time curve to time infinity.

Time frame:
Day 1, Week 2
Reported as:
Mean · [(hr)(ng)/mL]
Pharmacokinetic (PK) Assessments (AUC Inf)
[(hr)(ng)/mL]Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 1118 ± 48379 ± 117761 ± 3523279 ± 1693
Week 2164 ± 61544 ± 1551138 ± 4673606 ± 897
SecondaryPharmacokinetic (PK) Assessments CL (ml/hr/kg)

Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay

Time frame:
Day 1, Week 2
Reported as:
Mean · ml/hr/kg
Pharmacokinetic (PK) Assessments CL (ml/hr/kg)
ml/hr/kgDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 12459 ± 8972285 ± 11032697 ± 12852320 ± 1375
Week 21828 ± 9191509 ± 4822047 ± 7711777 ± 476
SecondaryPharmacokinetic (PK) Assessments t(1/2)

Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay. t1/2= elimination half life.

Time frame:
Day 1, Week 2
Reported as:
Mean · hour
Pharmacokinetic (PK) Assessments t(1/2)
hourDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 12.1 ± 0.851.8 ± 0.431.9 ± 0.791.9 ± 0.95
Week 21.9 ± 0.962.1 ± 0.81.9 ± 1.021.4 ± 0.35
SecondaryPharmacokinetic (PK) Assessments (Cmax)

Plasma concentrations of vamorolone were measured using a specific and validated liquid chromatography tandem mass spectrometry (LC-MS) assay

Time frame:
Day 1, Week 2
Reported as:
Mean · ng/mL
Pharmacokinetic (PK) Assessments (Cmax)
ng/mLDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Day 122.9 ± 13.475.9 ± 25.9199 ± 111855.6 ± 471
Week 232.2 ± 15.2124.7 ± 42.5252.2 ± 96970 ± 270
SecondaryMetabolites in Safety Testing (MIST) Assessment

A portion of each blood sample of the Week 2 (Day 14) pharmacokinetic assessment time points for the subjects receiving vamorolone 2 mg/kg/day was used for analysis of vamorolone metabolites.

Time frame:
Week 2 (Day 14)
Reported as:
Mean · % of total drug related exposure
Metabolites in Safety Testing (MIST) Assessment
% of total drug related exposureDose Level Group 3
M134.42 ± 2.79
M21.16 ± 0.06
M31.21 ± 0.07
M437.84 ± 3.78
M52.73 ± 0.17
Vamorolone22.64 ± 0.69

Adverse events

Collected over Adverse events will be recorded from the date of informed consent and through the time of the subject's last study visit. Serious adverse events will be recorded from the date of informed consent and for up to 30 days after final drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level Group 10/12 (0%)0/12 (0%)7/12 (58.3%)
Dose Level Group 20/12 (0%)0/12 (0%)6/12 (50%)
Dose Level Group 30/12 (0%)0/12 (0%)8/12 (66.7%)
Dose Level Group 40/12 (0%)0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 29
Most frequent other events
EventDose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4
Viral Upper Respiratory Tract InfectionInfections and infestations3/122/121/120/12
Pain in ExtremityMusculoskeletal and connective tissue disorders0/123/120/120/12
DiarrhoeaGastrointestinal disorders1/120/121/122/12
VomitingGastrointestinal disorders2/120/120/121/12
Upper-airway cough syndromeRespiratory, thoracic and mediastinal disorders0/122/120/120/12
Abdominal PainGastrointestinal disorders0/121/120/120/12
Abdominal Pain UpperGastrointestinal disorders0/120/121/120/12
ConstipationGastrointestinal disorders0/120/120/121/12
Faeces DiscolouredGastrointestinal disorders1/120/120/120/12
Lip SwellingGastrointestinal disorders1/120/120/120/12

Baseline characteristics

Age, Customized
Age, Customized(years)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Age5.2 ± 1.034.8 ± 0.834.7 ± 0.894.8 ± 0.754.9 ± 0.87
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Female00000
Male1212121248
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Hispanic or Latino01034
Not Hispanic or Latino121112944
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American10001
White1110121245
More than one race00000
Unknown or Not Reported01001
Region of Enrollment
Region of Enrollment(Participants)Dose Level Group 1Dose Level Group 2Dose Level Group 3Dose Level Group 4Total
Canada30227
Sweden04004
United States932620
United Kingdom00426
Israel03205
Australia02226
08

Study locations

12 sites
  • University of California Davis
    Davis, California 95616, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Ann & Robert H. Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75207, United States
  • Royal Children's Hospital
    Melbourne, Australia
  • Sydney Children's Hospital
    Westmead, Australia
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Schneider Children's Medical Center
    Petah Tikvah, 49202, Israel
  • Queen Silvia Children's Hospital
    Gothenburg, 41685, Sweden
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, Guglieri M, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, Kerchner L, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, Gordish-Dressman H, Hagerty L, Dang UJ, Damsker JM, Schwartz BD, Mengle-Gaw LJ, McDonald CM; CINRG VBP15 and DNHS Investigators. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020 Sep 21;17(9):e1003222. doi: 10.1371/journal.pmed.1003222. eCollection 2020 Sep. PubMed 32956407 ↗
  • Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ. Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. J Clin Pharmacol. 2020 Oct;60(10):1385-1396. doi: 10.1002/jcph.1632. Epub 2020 May 20. PubMed 32434278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of May 2018 and a completion of May 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2019, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2016
First posted
May 3, 2016
Start
Jun 2016
Primary completionActual
May 1, 2018
CompletionActual
May 1, 2018
Results first posted
Jan 2, 2019
Last update
Jan 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02760264
Lead sponsor
ReveraGen BioPharma, Inc.
Responsible party
Sponsor
First posted
May 3, 2016
Start date
Jun 2016
Primary completion
May 1, 2018
Completion
May 1, 2018
Results posted
Jan 2, 2019
Last update
Jan 2, 2019

Study contacts

Paula R Clemens, MD
study chair · University of Pittsburgh

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamorolone

Start the discussion